A study listed on ClinicalTrials.gov.
- Who can join
- Adults 25 to 50, women only.
- What you take
- Check ClinicalTrials.gov for this trial's study groups and what each group receives.
- How long it lasts
- The study runs about 4 months.
- What you get
- Costs vary by study. Ask the study team what this one covers, including the study medicine, visits and travel, before you sign the consent form.
What this study is for
Primary condition: Wrinkle.
Full scientific study title: Assess Impact of Microdroplet Hyaluronic Acid Filler on Skin Quality in Patients on Glucagon-like Peptide-1 Agonists.
Who can join
Adults 25 to 50, women only. A site coordinator confirms whether you qualify during a free screening visit. The exact medical requirements are below.
Full medical eligibility (for you and your doctor)verbatim from the registry
This is the exact wording from ClinicalTrials.gov, including clinical measures (lab values, imaging scores). Bring it to your doctor if any of it is unclear.
Key inclusion criteria
- Adult women aged 25-50 years.
- Fitzpatrick skin types I-VI.
- Current treatment with a stable dose of GLP-1 agonist medication for at least the last 6 months, for 16 of the enrolled subjects. Remaining 8 subjects should not be taking or have a history of taking a GLP-1 agonist therapy in the last year.
- Presence of moderate skin changes (as defined by Modified Griffiths' Scale, with an average score of 4-6) in the following criteria: skin radiance/brightness, skin elasticity, tone evenness, skin firmness, fine lines, global wrinkles, and skin smoothness (tactile and visual).
- Participants must maintain a stable weight, defined as no greater than a 10% weight change from screening/baseline and throughout the study.
Key exclusion criteria
- The presence of severe facial skin aging (as defined by Modified Griffiths' Scale, with an average score of 7-9) or minimal facial skin aging (as defined by Modified Griffiths' Scale, with an average score of 0-3).
- Females who are pregnant, planning a pregnancy, or currently breast feeding during the study.
- Any uncontrolled systemic disease.
- History of autoimmune connective tissue disease.
- Current use of immunosuppressive medication.
Where this trial runs
This trial has 1 sites across 1 state. Site contacts are listed for reference. They are not screening through this trial right now.
California1 site
- West Dermatology Research CenterSan Diego, California
Timeline
Scheduled start: November 1, 2025. Expected completion: March 2, 2026. Last updated on ClinicalTrials.gov: October 28, 2025.
Official source
Every Monday we check this trial against ClinicalTrials.gov, the federal registry for clinical research. Last checked September 4, 2026. Confirm the current status there before you contact a site:
Other GLP-1 clinical trials
Back to the full directory → or take the matching quiz if you want clinical trials filtered to your conditions and location.
